𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

✍ Scribed by Guangbi Yao; Chengwei Chen; Weilun Lu; Hong Ren; Deming Tan; Yuming Wang; Daozheng Xu; Zhengrong Jiang; Jessica Liu; Dong Xu; Laurie MacDonald; for the AI463023 Study Group

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
223 KB
Volume
1
Category
Article
ISSN
1936-0533

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of adefovir add-on lamivudine r
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B
✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45

Efficacy of entecavir in patients with c
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone
✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/

Telbivudine versus lamivudine in Chinese
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
✍ Jinlin Hou; You-Kuan Yin; Daozhen Xu; Deming Tan; Junqi Niu; Xiaqiu Zhou; Yuming 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudin